Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16086
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Trubiano, Jason | - |
dc.contributor.author | Aung, Ar Kar | - |
dc.contributor.author | Nguyen, Mary | - |
dc.contributor.author | Fehily, Sasha R | - |
dc.contributor.author | Graudins, Linda | - |
dc.contributor.author | Cleland, Heather | - |
dc.contributor.author | Padiglione, Alex | - |
dc.contributor.author | Peleg, Anton Y | - |
dc.date | 2016-06-07 | - |
dc.date.accessioned | 2016-07-26T04:15:21Z | - |
dc.date.available | 2016-07-26T04:15:21Z | - |
dc.date.issued | 2016-11 | - |
dc.identifier.citation | The Journal of Allergy and Clinical Immunology: In Practice 2016; 4(6): 1187-1193 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16086 | - |
dc.description.abstract | BACKGROUND:The difference in clinical presentation, causality assessments, and outcomes of patients with delayed antibiotic-associated cutaneous adverse drug reactions (AA-cADR) and nonantibiotic-associated (NA)-cADR is ill defined. OBJECTIVE: We examined the etiology of AA-cADR, with regard to the type of antibiotic exposure, allergy labeling, and patient outcomes, in comparison with NA-cADR. METHODS: A retrospective observational inpatient cohort study of cADR was performed from January 2004 to August 2014. Patients were divided into AA-cADR and NA-cADR groups for analysis. cADR was defined as erythema multiforme, fixed drug eruption, acute generalized erythematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS), drug-associated linear IgA disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis. RESULTS: Of the 84 patients with cADR, 48% were AA-cADR. Male sex (60% vs 32%, P = .004), median length of stay (14.5 vs 11 days, P = .05), median Charlson comorbidity index (3 vs 1, P = .03), and inpatient mortality (20% vs 5%, P = .04) were higher in AA-cADR compared with NA-cADR. The median drug latency was lower in AA-cADR (6 vs 20 days, P = .001). Sulfonamide antibiotics and glycopeptides were implicated in 20% of AA-cADR. DRESS was more frequently reported in AA-cADR. After cADR diagnosis, further antibiotic therapy was administered in 64% of patients, higher in AA-cADR (75%, 30 of 40) compared with NA-cADR (55%, 24 of 44) (P = .06). Fluoroquinolones (53% vs 21%, P = .02), glycopeptides (vancomycin and teicoplanin; 70% vs 38%, P = .05), and carbapenems (33% vs 13%, P = .11) were used more commonly in AA-cADR. CONCLUSIONS: Antibiotics were the cause of cADR requiring hospital admission in 48% of episodes, and were associated with longer length of stay, higher age-adjusted Charlson comorbidity index, shorter drug latency, and mortality. In AA-cADR, glycopeptide and sulfonamide antibiotic exposure predominated. | en_US |
dc.subject | Allergy | en_US |
dc.subject | Drug reactions | en_US |
dc.subject | Steven-johnson syndrome | en_US |
dc.subject | toxic epidermal necrolysis | en_US |
dc.title | A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | The Journal of Allergy and Clinical Immunology: In Practice | en_US |
dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Infectious Diseases, Alfred Health & Monash University, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Medicine, University of Melbourne, Parkville, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of General Medicine, Alfred Health, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Pharmacy, Alfred Health & Monash University, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Burns Unit, Alfred Health, Melbourne, Victoria, Australia | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27283055 | en_US |
dc.identifier.doi | 10.1016/j.jaip.2016.04.026 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-5111-6367 | - |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Trubiano, Jason | - |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Infectious Diseases | - |
crisitem.author.dept | Medicine (University of Melbourne) | - |
crisitem.author.dept | Centre for Antibiotic Allergy and Research | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.